Please wait while we load the requested 8-K report or click the link below:
https://last10k.com/sec-filings/report/1292519/000155837019006165/f8-k.htm
February 2024
February 2024
January 2024
December 2023
November 2023
November 2023
September 2023
March 2023
November 2022
October 2022
Please wait while we load the requested 8-K report or click the link below:
https://last10k.com/sec-filings/report/1292519/000155837019006165/f8-k.htm
Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were removed , added and changed by Invivo Therapeutics Holdings Corp..
Invivo Therapeutics Holdings Corp.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2019 10-K Annual Report includes:
Ticker: NVIVEvents:
CIK: 1292519
Form Type: 8-K Corporate News
Accession Number: 0001558370-19-006165
Submitted to the SEC: Fri Jul 19 2019 4:30:14 PM EST
Accepted by the SEC: Fri Jul 19 2019
Period: Wednesday, July 17, 2019
Industry: Surgical And Medical Instruments And Apparatus